PhoreMost and ThinkCyte collaborate to advance AI based drug discovery

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ distinctive technologies in high-throughput drug discovery, PhoreMost’s next-generation phenotypic screening platform, SITESEEKER®, and ThinkCyte’s AI-driven cell characterization and sorting platform, Ghost Cytometry®, with the aim of developing differentiated therapies for a range of diseases with unmet clinical need.

Driven by advances in cell-based phenotypic screening tools and novel target discovery technologies, the power of Phenotypic Drug Discovery (PDD) lies in its unmatched ability to find completely new drug targets and disease mechanisms, providing not only new drug candidates, but a better understanding of disease. PhoreMost’s SITESEEKER platform, based on the Company’s core proprietary ‘Protein Interference’ (PROTEINi) technology, probes the entire proteome to systematically unmask new and unanticipated druggable sites, directly linking them to useful therapeutic functions.

ThinkCyte has pioneered Ghost Cytometry, an approach that enables detection of novel, disease-related phenotypes. By combining SITESEEKER to identify novel druggable targets with Ghost Cytometry to identify subtle phenotypic changes in living cells, the partnership aims to develop an entirely unique approach to high-content phenotypic screening. The research partnership will drive ThinkCyte deeper into the field of early drug discovery and will contribute to PhoreMost’s mission of ‘Drugging the Undruggable®’.

PhoreMost has embraced the revolution in computational methods to transform the way we approach modern drug discovery,” said Dr. Benedict Cross, CTO of PhoreMost. “By combining ThinkCyte’s AI-based platform to detect novel, disease-related phenotypes with our SITESEEKER phenotypic screening platform, we hope to more efficiently uncover a broad range of novel targets and translate them into high-quality first-in-class therapeutic assets”

We are very excited about the research partnership with PhoreMost, a leader in applying innovative approaches and technologies to open up new druggable spaces.” said Waichiro Katsuda, CEO at ThinkCyte. “We have been privileged to work with drug discovery industry partners who share our vision of using AI to rethink traditional approaches in R&D and look forward to working together with PhoreMost to advance our technologies towards the shared goal of making meaningful impact for people suffering from serious diseases.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PhoreMost. (2022, December 16). PhoreMost and ThinkCyte collaborate to advance AI based drug discovery. News-Medical. Retrieved on June 19, 2024 from https://www.news-medical.net/news/20221216/PhoreMost-and-ThinkCyte-collaborate-to-advance-AI-based-drug-discovery.aspx.

  • MLA

    PhoreMost. "PhoreMost and ThinkCyte collaborate to advance AI based drug discovery". News-Medical. 19 June 2024. <https://www.news-medical.net/news/20221216/PhoreMost-and-ThinkCyte-collaborate-to-advance-AI-based-drug-discovery.aspx>.

  • Chicago

    PhoreMost. "PhoreMost and ThinkCyte collaborate to advance AI based drug discovery". News-Medical. https://www.news-medical.net/news/20221216/PhoreMost-and-ThinkCyte-collaborate-to-advance-AI-based-drug-discovery.aspx. (accessed June 19, 2024).

  • Harvard

    PhoreMost. 2022. PhoreMost and ThinkCyte collaborate to advance AI based drug discovery. News-Medical, viewed 19 June 2024, https://www.news-medical.net/news/20221216/PhoreMost-and-ThinkCyte-collaborate-to-advance-AI-based-drug-discovery.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Boehringer Ingelheim to use PhoreMost's SITESEEKER platform in new collaboration